Peptide Therapeutics
•41 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (41)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Peptide therapeutics (tirzepatide family) are a core part of Lilly's portfolio.
|
$985.74B |
$1063.02
+2.07%
|
|
ABBV
AbbVie Inc.
Nimble Therapeutics’ IL23R inhibitor and peptide platform contribute to AbbVie’s peptide therapeutics pipeline.
|
$388.96B |
$223.91
+1.69%
|
|
AZN
AstraZeneca PLC
Peptide therapeutics (e.g., oral GLP-1) represent a peptide-based modality in AZN's pipeline.
|
$282.78B |
$94.78
+3.90%
|
|
NVO
Novo Nordisk A/S
Semaglutide-based peptide therapeutics comprise the company’s differentiated platform (GLP-1 peptides) and core pipeline.
|
$248.55B |
$56.16
+1.91%
|
|
RDY
Dr. Reddy's Laboratories Limited
Peptide therapeutics focus within GLP-1 programs and related peptide APIs/formulations.
|
$11.53B |
$13.87
+0.36%
|
|
HIMS
Hims & Hers Health, Inc.
Peptide therapeutics manufacturing and development capabilities.
|
$7.85B |
$35.76
+3.03%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
IMCIVREE (setmelanotide) is a peptide-based therapeutic, fitting the peptide therapeutics category.
|
$6.77B |
$98.98
-2.83%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.24B |
$82.11
-2.46%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
DAYBUE (trofinetide) and ACP-101 intranasal carbetocin are peptide therapeutics, supporting a peptide therapeutics business.
|
$4.41B |
$26.75
+2.29%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
GLP-1 collaboration and peptide drug substance/finish capabilities map to Peptide Therapeutics.
|
$3.99B |
$13.02
+2.40%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$3.61B |
$32.10
-0.11%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
OPK
OPKO Health, Inc.
OPK-88006 is a dual GLP-1/glucagon peptide therapeutic (peptide therapeutics).
|
$1.02B |
$1.31
+2.73%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
Avexitide is a peptide-based GLP-1 receptor antagonist, aligning with the 'Peptide Therapeutics' tag.
|
$1.02B |
$11.28
-0.97%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$984.64M |
$29.00
-1.06%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$745.57M |
$4.30
-6.21%
|
|
BCYC
Bicycle Therapeutics plc
Bicycle molecules are fully synthetic peptide therapeutics used to target cancer.
|
$458.12M |
$6.54
-1.06%
|
|
ETON
Eton Pharmaceuticals, Inc.
ETON's portfolio includes peptide-based medicines (e.g., desmopressin in ET-600), which fits the Peptide Therapeutics investable theme.
|
$448.66M |
$16.60
-0.78%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$441.42M |
$8.67
+1.52%
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$360.97M |
$3.92
-4.03%
|
|
CATX
Perspective Therapeutics, Inc.
Pipeline includes peptide-based targeting constructs used to deliver radiopharmaceuticals.
|
$202.74M |
$2.83
+3.85%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
ELTX
Elicio Therapeutics, Inc.
Peptide components referenced in AMP program, aligning with Peptide Therapeutics.
|
$128.42M |
$8.03
+2.16%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-114 is a GLP-1/GLP-2 dual-agonist peptide program, placing the company in the peptide therapeutics space.
|
$97.74M |
$1.39
+1.84%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$83.78M |
$8.19
-7.72%
|
|
ENTX
Entera Bio Ltd.
Entera Bio develops peptide therapeutics (EB613, EB612, OPK-88006) and related oral peptide programs.
|
$80.82M |
$1.60
-9.60%
|
|
VANI
Vivani Medical, Inc.
Lead programs NPM-115 and NPM-139 are peptide-based GLP-1 receptor agonists, aligning with Peptide Therapeutics.
|
$74.65M |
$1.25
-0.79%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Peptide therapeutics (AI-designed GLP-1 peptides) being developed as internal assets.
|
$74.24M |
N/A
|
|
RNTX
Rein Therapeutics Inc.
LTI-3.00 is described as a peptide therapeutic, placing the company in the Peptide Therapeutics category.
|
$29.36M |
$1.23
-2.38%
|
|
CUE
Cue Biopharma, Inc.
The platform's peptide-MHC components align with Peptide Therapeutics as a major product modality.
|
$25.93M |
$0.33
+9.43%
|
|
VTGN
VistaGen Therapeutics, Inc.
PH94B and related pherine candidates are peptide-based, aligning with peptide therapeutics.
|
$22.09M |
$0.71
-0.69%
|
|
PYPD
PolyPid Ltd.
GLP-1 program uses the PLEX platform to deliver long-acting peptide therapeutics (GLP-1) for metabolic diseases.
|
$21.44M |
$4.57
+2.24%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$16.90M |
$1.94
+0.52%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-VA's GDNF-based therapy could be categorized as peptide therapeutics (protein/peptide modality).
|
$14.05M |
$1.03
-2.36%
|
|
BIVI
BioVie Inc.
BIV201 is a continuous-infusion peptide therapy (terlipressin) for liver cirrhosis, mapping to 'Peptide Therapeutics'.
|
$9.87M |
$1.41
+7.63%
|
|
BLRX
BioLineRx Ltd.
Motixafortide is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$6.91M |
$2.88
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Lead asset hCDR1 is a peptide-based therapeutic, fitting the Peptide Therapeutics category.
|
$3.45M |
$0.63
-0.65%
|
|
SILO
Silo Pharma, Inc.
Peptide Therapeutics applies to SPU-16 CNS-homing peptide and related peptide-based delivery/therapeutics platforms.
|
$3.33M |
$0.37
+3.18%
|
|
BZYR
Burzynski Research Institute, Inc.
Antineoplastons are peptide-based therapeutics; core product category is peptide therapeutics.
|
$2.50M |
$0.02
|
|
AAGH
America Great Health
Focus on peptide/protein therapeutics as a core research and therapeutic development area.
|
$2.12M |
$0.00
|
Loading company comparison...
Loading industry trends...
Loading research report...
